Rajan Dewar

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker
    Rajan Dewar
    Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston MA, USA
    Cancer Biol Ther 11:552-8. 2011
  2. doi request reprint Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology
    Rajan Dewar
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Arch Pathol Lab Med 135:422-9. 2011
  3. pmc Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells
    Octavian Bucur
    Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America Institute of Biochemistry of the Romanian Academy, Bucharest, Romania
    PLoS ONE 8:e77390. 2013

Collaborators

  • Allen M Gown
  • Oluwole Fadare
  • Octavian Bucur
  • Bodvael Pennarun
  • Roya Khosravi-Far
  • Thierry Bertomeu
  • Ioana Goganau
  • Stefana Maria Petrescu
  • Andreea Lucia Stancu

Detail Information

Publications3

  1. pmc Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker
    Rajan Dewar
    Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston MA, USA
    Cancer Biol Ther 11:552-8. 2011
    ..Additionally, proteasomal inhibition by bortezomib may be a promising therapeutic option in Philadelphia-positive ALL, where FoxO3 is downregulated...
  2. doi request reprint Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology
    Rajan Dewar
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Arch Pathol Lab Med 135:422-9. 2011
    ....
  3. pmc Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells
    Octavian Bucur
    Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America Institute of Biochemistry of the Romanian Academy, Bucharest, Romania
    PLoS ONE 8:e77390. 2013
    ..These results open novel possibilities for the treatment of Bcr-Abl-positive leukemias, especially in the imatinib, dasatinib and nilotinib-resistant CML cases. ..